Pharma Industry, Pharma News, Indian Pharmaceutical Company News, International Pharmaceutical Company News update
Lupin forays into the domestic OTC drug market

Pegged at over Rs 18,862 crore by a Nicholas Hall 2017 report, the Indian OTC market is expected to grow at a compounded annual growth rate (CAGR) of 9 percent to cross Rs 44,115 crore.

 
 
After capping prices of stents, concerns are that the government may now be moving towards expanding the ambit of price caps to other consumables in healthcare.
On December 7th, Mylan launched 'HepBest', which it called, "the first drug approved in eight years for management of chronic Hepatitis B infection in India." 
The Centre's decision to allow chemists to sell homeopathic medicines could be a significant move. Here's why.
Advertisement